Trevi Therapeutics, Inc. (TRVI): Results of Operations and Financial Condition
Trevi Therapeutics, Inc. (TRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 trvi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase
How this was made
The 30-second read
Why it matters
The 8-K provides fresh operational milestones (Phase 3 OCEAN-1 and Phase 2b LAKE initiated in Q2 2026), planned next steps (OCEAN-2 initiation in Q3 2026, FDA meeting for non-IPF ILD strategy), and financial runway (cash into 2030). These items can shift valuation models tied to development progress and financing overhang.
Market read
Investors get a new execution checkpoint for Haduvio’s development program plus a quantified cash runway, which can influence near-term sentiment and longer-dated probability-weighted outcomes.
What to watch
Key near-term risk is enrollment speed and SSRE execution in LAKE (sample size re-estimation expected in Q4 2026), plus the outcome of the FDA meeting request for non-IPF ILD.
Background
Trevi Therapeutics is a clinical-stage biopharmaceutical developing Haduvio (oral nalbuphine ER) for chronic cough across IPF-related chronic cough, non-IPF ILD-related chronic cough, and refractory chronic cough.
Ticker impact
Trevi Therapeutics reports Q2 2026 results and says it initiated Phase 3 OCEAN-1 and Phase 2b LAKE, with OCEAN-2 planned for Q3 2026.
Likely positive bias for TRVI as investors focus on new trial starts, FDA alignment steps, and runway guidance; magnitude depends on how the market values the updated timelines.
This is a primary SEC 8-K disclosure with concrete trial initiation dates, expected topline windows (2027-2028), and a quantified cash runway into 2030 after an April equity offering.
Market effects
Adds incremental signal on chronic cough drug development timelines and FDA engagement cadence for ILD-related indications.
Limited, company-specific biotech catalyst rather than a broad regional driver.
Primarily US regulatory and clinical execution; limited spillover beyond specialty biotech investors.
Counterpoint
Trial initiation and runway guidance may already be partially anticipated; without new efficacy data, the market may fade the news if burn rate or enrollment pace disappoints.
Key entities
- companyTrevi Therapeutics, Inc.
Nasdaq-listed clinical-stage biopharmaceutical developing Haduvio for chronic cough indications.
- productHaduvio (oral nalbuphine ER)
Investigational therapy targeting chronic cough in IPF-related chronic cough, non-IPF ILD-related chronic cough, and refractory chronic cough.
- clinical_trialOCEAN-1, OCEAN-2
Phase 3 trials in IPF-related chronic cough; OCEAN-1 initiated in Q2 2026, OCEAN-2 expected to initiate in Q3 2026.
- clinical_trialLAKE trial
Phase 2b trial in refractory chronic cough; initiated in Q2 2026 with SSRE expected after 50% treatment completion in Q4 2026.
- regulatorFDA
Company plans to meet to align on the non-IPF ILD-related chronic cough development plan and regulatory strategy.
